Legislature(2023 - 2024)DAVIS 106
03/14/2024 03:00 PM House HEALTH & SOCIAL SERVICES
Note: the audio
and video
recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
Audio | Topic |
---|---|
Start | |
Board of Direct Entry Midwives | |
HB363 | |
HB187 | |
HB205 | |
Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
+ | TELECONFERENCED | ||
+= | HB 187 | TELECONFERENCED | |
*+ | HB 363 | TELECONFERENCED | |
*+ | HB 205 | TELECONFERENCED | |
+ | TELECONFERENCED | ||
HB 187-PRIOR AUTH EXEMPT FOR HEALTH PROVIDERS 4:42:43 PM CHAIR PRAX announced that the next order of business would be HOUSE BILL NO. 187, "An Act relating to utilization review entities; exempting certain health care providers from making preauthorization requests for certain services; and providing for an effective date." 4:44:22 PM CHAIR PRAX opened public testimony on HB 187. JEANNIE MONK, Senior Vice President, Alaska State Hospital & Healthcare Association, testified in support of HB 187, saying it would reduce the wait time for certain healthcare services by exempting healthcare providers from the preauthorization process. She said that HB 187 represents a step forward in ensuring timely access to essential medical care. She said that prior authorization can be extremely frustrating and stressful for patients and said the last thing a patient wants to worry about is whether or not their insurance company will cover their medical bills. She said for patients in rural areas, the issue of prior authorization is exacerbated by the remote nature of rural medical care. She emphasized that the prior authorization process is extremely time consuming for medical providers as well. Often a healthcare provider will hire teams of staff just to manage insurance and prior authorization requests. She said the proposed legislation would strike a good balance between all aspects of the prior authorization process, and she urged the committee to pass HB 187. 4:48:00 PM REPRESENTATIVE FIELDS asked how many medical conditions exist where the treatment might be longer than 12 months. MS. MONK said she would follow up with an answer later. 4:48:37 PM REPRESENTATIVE RUFFRIDGE asked Representative Fields to clarify his question as to how it relates to prior authorization. REPRESENTATIVE FIELDS asked if a hypothetical treatment regime that would need to be executed for longer than 12 months is addressed in HB 187. 4:49:36 PM REPRESENTATIVE JESSE SUMNER, Alaska State Legislature, as prime sponsor, in response to Representative Fields, cited psoriasis medication as an ongoing treatment regime and said that the exemption for prior authorization, as addressed under HB 187, is for the healthcare provider, not the patient. CHAIR PRAX asked Ms. Monk how often prior authorization requests are denied and how long payment would take if a request were approved. MS. MONK replied that it varies greatly, but there is no data set on it. She said there are hundreds of procedures all over Alaska that have to be authorized every day. 4:52:05 PM TAMMY THIEL, Executive Director, Denali Oncology Group, testified in support of HB 187. She gave context to the primary role of the Denali Oncology Group (DOG) and explained how the current prior authorization process is negatively affecting medical care in Alaska. She said HB 187 prescribes a solution for these issues by introducing the concept of a "gold card" that grants exemption to healthcare providers who consistently follow evidence-based medicine and achieve an 80 percent approval rating on prior authorization requests. She said this could greatly streamline the process of prior authorization and urged the committee's support for HB 187. 4:55:11 PM PAM VENTGEN, Executive Director, Alaska State Medical Association, testified in support of HB 187. She said that prior authorization is a process that serves a purpose but can often inhibit timely and quality healthcare. She said the "gold card" provision of HB 187 is sensical and would make the process of prior authorization smoother for all parties involved. She gave a note on statistics surrounding prior authorization approval/disapproval rates, along with patient outcomes depending on the approval or disapproval of the prior authorization. She cited a survey from the American Medical Association (AMA) that found that prior authorization requirements delay necessary treatment and care in 94 percent of cases. She said the physical, emotional, and financial impact to patients from delays caused by prior authorization are significant and devastating, and change should be made. She said that HB 187 makes sound and logical changes to these problems and urged the committee's support of HB 187. 4:59:48 PM MARC REECE, Director of Public Policy, AETNA, testified in opposition to HB 187. He said that HB 187 is not a good solution to the ailments that currently exist in the prior authorization system. He explained that the purpose of prior authorization is to ensure that healthcare is paid for and administered as soon as possible and said that HB 187 doesn't help with that purpose. He said that the bill sponsor doesn't recognize the impact of the proposed legislations' proposed "gold card" exemption program. The 80 percent threshold is far lower than every other state that has tried to implement an exemption program. 5:03:06 PM REPRESENTATIVE MINA asked what mechanisms are currently in place that insurance companies can pursue to reduce the wait time for prior authorization. MR. REECE responded that AETNA is actively trying to reduce the prior authorization approval process by removing certain services from prior authorization and by automating the approval process through clinical standards that must be met. 5:05:14 PM PREET KLAUR, Policy & Legislative Manger, Premera Blue Cross Blue Shield of Alaska, testified in opposition to HB 187. She said the proposed bill would be costly and confusing for insurance companies and their members. She warned that HB 187 would increase the risk for adverse medical events, citing an unnamed study that found that over 10 percent of authorization reviews prevented adverse drug events and medical errors. She emphasized that prior authorization is a critical tool in ensuring that healthcare is cost-effective and safe, and added that all prior authorization requests are resolved within 5 days, or within 24 hours if it is an emergency request. She explained an existing support structure for medical providers that allows for a reevaluation process if there were wrongful disapproval of a prior authorization request. REPRESENTATIVE MINA asked what mechanisms Premera Blue Cross Blue Shield of Alaska was pursuing to reduce prior authorization approval times. MS. KLAUR answered that Premera Blue Cross Blue Shield of Alaska has created a reevaluation process for a denied approval and implemented an electronic portal online for easier access to information regarding its prior authorization approval. 5:10:18 PM REPRESENTATIVE MINA asked whether HB 187 applies to the healthcare plans utilized by the State of Alaska. STEVE RAMOS, Acting Chief Health Administrator, Division of Retirement & Benefits, Department of Administration, answered that HB 187 is housed under Title 21 under Alaska Statute, and the Alaska Care plans as administered by the Division of Retirement and Benefits are not insurance plans, so they are subject to Title 39 under Alaska Statute. REPRESENTATIVE MINA asked Representative Sumner, "Is your intent to also cover the state plan and [Employee Retirement Income Security Act] (ERISA) plans or are you only sticking to Title 21?" REPRESENTATIVE SUMNER answered that is correct. 5:11:56 PM CHAIR PRAX, after ascertaining there was no one else who wished to testify, closed public testimony on HB 187. CHAIR PRAX announced that HB 187 was held over.